Almirall S A : joins the AMR Action Fund to support the fight against antimicrobial resistance

Almirall joins the AMR Action Fund to support the fight against antimicrobial resistance 10 July 2020

• Antimicrobial resistance (AMR) is considered one of the most urgent global medical challenges
• More than 20 leading biopharmaceutical companies across the globe have raised nearly $1B of new funding to support clinical research of innovative antibiotics to address this topic

Almirall, S.A. (ALM) has announced today its participation in the AMR Action Fund, a ground-breaking partnership to join forces against antimicrobial resistance (AMR), which aims to bring 2-4 new antibiotics to patients by 2030. The AMR Fund is an initiative of the international body representing the R&D pharmaceutical industry and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). More than 20 biopharmaceutical companies across the globe have raised nearly $1B new funding to support clinical research of innovative antibiotics to address the most resistant bacteria infections. The Fund will focus on urgent public health needs and will provide much needed financial resources, as well as important technical support to help biotech companies bring novel antibiotics to patients.

Through this new initiative, Almirall will contribute to strengthen and accelerate antibiotic development, focusing on urgent public health needs. Almirall's commitment to improving patients' quality of life means forging ahead with all R&D initiatives coming from different institutions, as R&D is in the DNA of Almirall's identity, developing new and effective treatments.

With this investment from leading biopharmaceutical companies, the AMR Action Fund will be the largest collective venture ever created to address AMR. The AMR Action Fund will invest in innovative antibacterial treatments which make a significant difference in clinical practice. It will also provide technical support to portfolio companies to strengthen antibiotic development and bring together a broad alliance of industry and non-industry stakeholders to create market conditions that enable sustainable investment in the antibiotic pipeline.

About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying science to provide medical solutions to patients and future generations. Our efforts are focused on fighting skin health diseases and helping people feel better. We support healthcare professionals in their continuous improvements, providing our innovative solutions where they are needed.

The company was founded over 75 years ago and has its headquarters in Barcelona. It is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key source of value creation for society because of its commitment to its principal shareholders and its mission to help patients by understanding their challenges and using science to provide solutions for real life. Total Revenues in 2019 were more than 900 million euros. Almirall has c. 1,800 employees.

For more information, please visit almirall.com